Wilfried A M Bakker
Affiliation: National Institute for Public Health and the Environment
Country: The Netherlands
- Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPVWilfried A M Bakker
National Institute for Public Health and the Environment, Vaccinology Unit, P O Box 1, 3720BA Bilthoven, The Netherlands
Vaccine 29:7188-96. 2011..Finally, the planned technology transfer to vaccine manufacturers in low and middle-income countries is discussed...
- Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccinesJanny Westdijk
National Institute for Public Health, Unit Vaccinology, Antonie van Leeuwenhoeklaan 9, 3720 AL Bilthoven, The Netherlands
Vaccine 29:3390-7. 2011..The latter observations are in line with data from human trials. This suggests that a higher dose of Sabin-IPV type 2 to compensate for the lower rat immunogenicity may not be necessary...
- Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strainsPauline Verdijk
Vaccinology Unit, RIVM, Antonie van Leeuwenhoeklaan 9, PO Box 1, 3720 BA Bilthoven, The Netherlands
Expert Rev Vaccines 10:635-44. 2011..Sabin-IPV is under development by several manufacturers. This article gives an overview of results from clinical trials with Sabin-IPV and discusses the requirements and challenges in the clinical development of this novel IPV...
- Innovative IPV from attenuated Sabin poliovirus or newly designed alternative seed strainsAhd Hamidi
National Institute for Public Health and the Environment RIVM, Centre for Infectious Disease Control CIb, Vaccinology Unit, P O Box 1, 3720 BA Bilthoven, The Netherlands
Pharm Pat Anal 1:589-99. 2012..Currently, such work is mainly carried out by research institutes and universities and therefore clinical data are not available. ..